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background:  Transcatheter aortic valve replacement (TAVR) for calcific aortic stenosis provides results comparable to surgery in patients 
at extreme/high operative risk. The most frequent complication, permanent pacemaker (PPM) implantation, has not been associated with 
increased cardiovascular death though additional studies are needed. The present analysis evaluates the incidence and predictors of the 
need for PPM at 30 days following implantation of the repositionable and fully retrievable Lotus Aortic Valve Replacement System (Boston 
Scientific, Marlborough, MA) in a cohort of 250 patients.
methods:  In the prospective, single arm, multicenter REPRISE II study, 120 symptomatic, high surgical risk patients with calcified aortic 
stenosis and annulus of 19-27mm received a transfemoral 23mm or 27mm Lotus Valve. An additional 130 patients were enrolled to create 
a preplanned, pooled extended cohort of 250 patients. Echocardiography, CT, and EKG data were evaluated by independent core labs.
results:  Mean age was 84.0 years, 52% were female, 77% were NHYA Class III/IV at baseline, and mean STS score was 6.5±4.2%. 
A total of 72 (28.9%) patients underwent new PPM implantation post TAVR. At 30 days, 51.4% had a paced rhythm. The most frequent 
indication for PPM implantation was 3rd degree AV block (59/72, 82%). Baseline right bundle branch block (RBBB) was present in 27.8% 
(20/72) and a new conduction disturbance was noted post-balloon valvuloplasty in 34.7% (25/72). Greater than 10% overstretch of the 
LVOT by perimeter was observed in 61.1% (44/72) and of the annulus in 34.7% (25/72) of PPM patients. Significant independent predictors 
of PPM at 30 days included baseline RBBB (odds ratio [OR] 11.4; 95% CI: 4.1, 31.6; P<0.001) and LVOT overstretch (OR 1.1, 95% CI: 1.0, 
1.1; P<0.001).
Conclusion:  Baseline RBBB and LVOT overstretch were significant independent predictors of the need for PPM at 30 days following Lotus 
Valve implantation. Only half the patients with an implanted PPM were paced at 30 days. The availability of additional valve sizes, including 
21mm and 25mm diameter valves, may reduce the incidence of overstretch and decrease the need for PPM with the Lotus Valve.
